Aravive Inc

Aravive — Versartis — Investor Day (September 2016)

127 slides from Aravive's investor day presentation, Sep 15, 2016

  1. Slide 1: Investor Day | September 15, 2016

    Investor Day | September 15, 2016

  2. Slide 2: Welcome

    Welcome Jay Shepard | Chief Executive Officer

  3. Slide 3: Safe Harbor

    Safe Harbor This presentation and the accompanying oral commentary contain forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of future performance and are subject to risks and u

  4. Slide 4: Endocrine-Focused Biopharmaceutical Company Developing Somavaratan

    Endocrine-Focused Biopharmaceutical Company Developing Somavaratan, a Novel, Long-Acting form of Recombinant Human Growth Hormone to Treat the Orphan Disease of Growth Hormone Deficiency

  5. Slide 5: Today's Agenda

    Today’s Agenda 8:00 am Welcome, Vision & Strategy Jay Shepard Chief Executive Officer, Versartis, Inc. Introductions: PGHD Speakers Colin Hislop, MD Chief Medical Officer, Versartis, Inc. Pediatric Growth Hormone Deficiency: A 50 Year Perspective Alan Rogol, MD, PhD Professor Emeritus, Pediatrics an

  6. Slide 6: Introducing the Versartis Team

    Introducing the Versartis Team: Significant Expertise in GHD Manufacturing, Development & Commercialization Jay Shepard President & CEO >33 Years Pharmaceutical, Biotech, Drug Delivery Expertise Commercialization of Specialty Products, M&A Expertise Joshua Brumm CFO Led Successful IPO and Follow on

  7. Slide 7: 2016: Achieving Our Objectives

    2016: Achieving Our Objectives PGHD AGHD Activities Supporting BLA Filing & Launch Readiness Complete enrollment PGHD Phase 3 VELOCITY trial-mid 2016 ANNOUNCED August 22 (n=137) Complete Phase 2 portion of J14vr5 Japan study, move to Phase 3 Phase 2 enrolled; Phase 3 initiation on track Q4 2016 Comp

  8. Slide 8: 2017-2018 Strategic Objectives

    2017-2018 Strategic Objectives Complete Phase 3 VELOCITY trial J14vr5 Phase 3 trial in Japan Initiate AGHD Phase 3 Continued KOL development Device & CMC validation Prepare for US/EU regulatory submissions Continue growing organization & executing on plan Commercial strategy & launch preparation Exp

  9. Slide 9: Somavaratan's Data to Date; Focus for Today's Program

    Somavaratan’s Data to Date Focus For Today’s Program Market Expectations Commercial Readiness Somavaratan continues to demonstrate a strong safety and efficacy profile as seen in 24-month data VISTA study patients starting 4th year of Treatment on Somavaratan Evidence that Somavaratan is working in

  10. Slide 10: GROW16 Versartis Sponsored Global Market Research

    GROW16 Versartis Sponsored Global Market Research GH Research and Observations Worldwide 2016 Market Needs & Expectations Commercial Preparation Objective: To better understand physician unmet needs, perceptions, and attitudes towards current growth hormone treatment and market dynamics Conducted vi

  11. Slide 11: GROW16: Potential for Market Growth, Earlier Dx/Tx

    Years EU5 US JP GROW16: Potential for Market Growth, Better Outcomes with Earlier Dx/Tx Average Age of Diagnosis and First Treatment Market Needs & Expectations Commercial Preparation

  12. Slide 12: GROW16: Primary Treatment Goals are Long-Term Growth & Height

    GROW16: Primary Treatment Goals are Long-Term Growth & Height Physicians Primary Goal of Treatment when Treating PGHD Patients EU5 (B) US (A) JP (C) Market Needs & Expectations Commercial Preparation

  13. Slide 13: GROW16: HV Expectations Surprisingly Low

    EU5 US Japan GROW16: HV Expectations Surprisingly Low in This Sample Expected Height Velocity in the 1st and 2nd Year of Treatment Physicians Participating in Clinical Trials had Higher HV Expectations than Peers: ~9/10 cm Y1 HV vs ~7/8cm Y1 HV in US Better Compliance and Patient Selection were Reas

  14. Slide 14: A Range of Expectations for First Year Growth

    A Range of Expectations for First Year Growth Twice-Monthly Somavaratan Well Positioned in the Range with Potential For Enhanced Growth on Higher Phase 3 Dose Historical Databases Versartis Market Research Market Needs & Expectations Commercial Preparation 8.5 cm Somavaratan Year 1 HV with Twice-mon

  15. Slide 15: Somavaratan Could Address Unmet Needs

    Unmet Need Unmet Need Unmet Need % Physicians Rating Top -2 Box out of 7 GROW16: Product Attributes: Importance vs Current Performance Somavaratan Could Address Unmet Needs: Twice-Monthly Dosing, with Data to Date Showing 99% Treatment Adherence & Similar Safety/Efficacy to Daily rhGH Market Needs &

  16. Slide 16: Manufacturing and Supply Agreement with Owen Mumford

    Manufacturing and Supply Agreement with Owen Mumford Over six decades of experience in developing medical device solutions for own brands & for pharmaceutical/diagnostic companies including Johnson & Johnson, Janssen, Novartis, Bayer, Merck Sorono and others (one of the top 3 in the world) Manufactu

  17. Slide 17: Single-Use Auto-injector Designed for Ease of Use

    Single-Use Auto-injector Designed for Ease of Use, Safety, Comfort Auto-Injector Commercial Preparation [image placeholder] Simple injection procedure Suitable for self-injection >8 years Room Temp Storage Disposable 29G thin-wall needle Multiple options with fine dosing adjustments

  18. Slide 18: Versartis and Teijin Establish Strategic Alliance in Japan

    Versartis and Teijin Establish Strategic Alliance in Japan Teijin receives exclusive license to commercialize & further develop somavaratan in Japan Versartis to receive $40 million upfront, and up to $125 million in potential milestones: Development milestone of $35 million Regulatory milestones up

  19. Slide 19: Teijin Transaction is a Strong Strategic Fit

    Teijin Transaction is a Strong Strategic Fit 6th largest Japanese company in Pharmaceutical sales Licensing partnerships with Merck, Ipsen, Boehringer Ingelheim, Takeda & Sanofi Highly Successful commercial track record in very competitive product areas of ENDOCRINE & METABOLIC DISEASES Existing fra

  20. Slide 20: Summary

    Summary Data to Date suggest somavaratan is working Executing on the plan Somavaratan is well positioned to address market Clinical program designed to support commercial success

  21. Slide 21: Investor Day | September 15, 2016

    on VERSARTIS Investor Day | September 15, 2016

  22. Slide 22: Introductions: PGHD Speakers

    Introductions: PGHD Speakers Colin Hislop, MD | Chief Medical Officer

  23. Slide 23: Alan D. Rogol, MD, PhD

    Alan D. Rogol, MD, PhD Dr. Rogol is Professor Emeritus, Pediatrics and Pharmacology, at the University of Virginia School of Medicine. He received his doctorates in medicine and physiology (Endocrinology) from Duke University and completed a residency in pediatrics at the Johns Hopkins Hospital. Fol

  24. Slide 24: Michael Stalvey, MD

    Michael Stalvey, MD Dr. Michael Stalvey is an Assistant Professor and Fellowship Program Director in the Department of Pediatrics at the University of Alabama at Birmingham, School of Medicine. He received his M.D. from the University of Florida College of Medicine, conducted his residency there in

  25. Slide 25: Pediatric Growth Hormone Deficiency: A 50 Year Perspective

    Pediatric Growth Hormone Deficiency A 50 Year Perspective Alan D. Rogol, MD, PhD Professor, Emeritus University of Virginia Charlottesville, VA USA

  26. Slide 26: Growth Hormone (GH)

    Growth Hormone (GH) 191 amino acid single chain peptide consisting of several isoforms with the 22 kDa for the most prominent Regulates production of IGF-I Promotes skeletal growth

  27. Slide 27: Growth Hormone (GH) Metabolic actions

    Growth Hormone (GH) Metabolic actions Rapid and large increase in REE Increased fat oxidation Increased protein and glucose synthesis Anabolic, lipolytic and weakly natriuretic Increases muscle mass, bone formation and total body water Decreases fat mass

  28. Slide 28: Which Children Require Evaluation for GH Deficiency?

    Which Children Require Evaluation for GH Deficiency? Growth failure suggested by a height- for-age curve has deviated downwards across two major height percentile curves eg, from above the 25th percentile to below the 10th percentile Or if the child is growing slower than the following rates: Age tw

  29. Slide 29: Which Children Require Evaluation for GH Deficiency?

    Which Children Require Evaluation for GH Deficiency? Severe short stature (eg, height ≤-2.5 SD [0.6th percentile]), or less severe short stature combined with growth failure Features that raise concerns for hypothalamic-pituitary dysfunction with decelerating growth, even if the child's height is wi

  30. Slide 30: GH Therapy for Childhood GH Deficiency

    GH Therapy for Childhood GH Deficiency Current Daily rhGH Treatment Approach in the US Routine administration by daily injection Administered subcutaneously Nocturnal administration Storage considerations Relatively benign safety profile Great variety in injection devices Injection practices determi

  31. Slide 31: GH Therapy for Childhood GH Deficiency: Daily Administration

    GH Therapy for Childhood GH Deficiency Daily administration remains inconvenient: Painful Distressing to some patients May lead to: non-compliance Reduced efficacy Increased health-care costs

  32. Slide 32: Poor Compliance Leads to Slower Growth

    Poor Compliance Leads to Slower Growth Cutfield et al. 2011

  33. Slide 33: Predictors of Response to rhGH

    Predictors of Response to rhGH Predictors of height response to growth hormone treatment include1,2: Younger age at the start of therapy Greater deviation of target height (genetic potential) from actual height Lower maximum GH stim test level Body weight Total GH dose Birth weight Duration of treat

  34. Slide 34: Predictors of Response to GH Therapy

    Predictors of Response to GH Therapy Factors predicting response to GH are derived from two very large databases: KIGS: Pfizer International Growth Database (previously known as the Kabi International Growth Study)1 NCGS: National Childhood Growth Study in North America2 Together, these factors pred

  35. Slide 35: Expected Response to GH Therapy

    Expected Response to GH Therapy When given for the treatment of growth hormone deficiency, growth hormone therapy is clearly effective If GH is administered at an early age, patients can achieve adult height within the midparental target height range1,2 Prediction of adult height as a function of th

  36. Slide 36: Defining "Good" Response

    Defining “Good” Response HV should be monitored to determine whether the growth response is adequate Growth should be compared with curves generated from a population of similarly treated children with growth hormone deficiency Target HV >75th percentile curve or >1 SD above the mean HV HV can also

  37. Slide 37: Defining "Good" Response: Ongoing Monitoring

    Defining “Good” Response Ongoing monitoring: Adequate IGF-I response after first month of treatment- IGF-I ~1 SD above the mean for age IGF-I is made in the liver in response to GH Recheck length or height at least every 4 to 6 months (or every 2 to 3 months in infants) IGF-I levels every 6 to 12 mo

  38. Slide 38: HV During First and Second Years of Daily GH Therapy

    HV During First and Second Years of Daily GH Therapy Related to Age at Treatment Onset: KIGS Database Ranke et al. J Clin Endocrinol Metab. 2010; 95:1229.

  39. Slide 39: HV During First Year of Tx in NCGS

    HV During First Year of Tx in NCGS Height velocity below the -1 SD curve is considered poor response Bakker, et al. J Clin Endocrinol Metab. 2008; 93:352.

  40. Slide 40: Treatment Goals: HV & Adult Height

    Treatment Goals: HV & Adult Height First year HV matters: Make as normal as possible “now” Most important for the smallest children The end goal is adult height An estimate of a child's genetic height potential can be obtained by calculation of the midparental height Based upon the heights of both p

  41. Slide 41: Long-acting Endocrine Agents

    Long-acting Endocrine Agents Daily GH does not mimic physiologic growth hormone secretion and it works Does this matter? Formulations for endocrine-active agents have long been part of the therapeutic armamentarium of endocrinologists GnRH agonist analogs Testosterone Medroxyprogesterone acetate hCG

  42. Slide 42: Long-acting Growth Hormone

    Long-acting Growth Hormone What are we looking for from a Long-Acting form of GH? Safety considerations No substantial differences in clinical effects when compared to daily administration Adherence/Compliance

  43. Slide 43: Growth Hormone Research Society Perspective on Long-Acting GH

    Growth Hormone Research Society Perspective on the Development of Long-Acting GH There is a clinical need for a safe and effective long-acting growth hormone treatment for which improved treatment adherence is attainable1 Development of a long-acting form of rhGH with long-term effectiveness may pot

  44. Slide 44: Investor Day | September 15, 2016

    Investor Day | September 15, 2016

  45. Slide 45: Somavaratan Treatment for Pediatric GHD: VISTA Study Results

    Somavaratan (VRS-317) Treatment for Pediatric Growth Hormone Deficiency (GHD): VISTA (13VR3) Study Results Michael Stalvey, MD Assistant Professor, Fellowship Program Director Department of Pediatrics, Division of Pediatric Endocrinology University of Alabama at Birmingham

  46. Slide 46: Growth Hormone Research Society Consensus Statement

    Growth Hormone Research Society Consensus Statement1 “Long-acting growth hormone compounds may represent an advance over daily GH injections because of increased convenience and differing pharmacodynamic properties, providing the potential for improved adherence and outcomes.” Growth Hormone Researc

  47. Slide 47: Recombinant Human Growth Hormone for Pediatric GHD

    Recombinant Human Growth Hormone (rhGH) for Treatment of Pediatric Growth Hormone Deficiency (GHD) Therapeutic potential of daily rhGH is well established and has been the primary treatment for pediatric GHD for three decades1,2 Current challenges with daily rhGH preparations include burden of daily

  48. Slide 48: Challenges With Adherence to Daily Growth Hormone Treatment

    Challenges With Adherence to Daily Growth Hormone Treatment Children with growth hormone deficiency (GHD) are often treated for multiple years with daily injections of recombinant human growth hormone (rhGH) replacement therapy, currently the only treatment available in North America and Europe 7 ye

  49. Slide 49: Noncompliance to Daily rhGH Associated With Suboptimal Response

    Noncompliance to Daily rhGH Associated With Suboptimal Response In a national survey of GH compliance by children in New Zealand (N=177), overall rate of noncompliance (≥1 missed injection/week, based on returned GH vials) was 66%1 Height velocity (HV) SDS and linear growth increased with treatment

  50. Slide 50: Poor Adherence to rhGH Therapy Results in Suboptimal Growth

    Poor Adherence to rhGH Therapy Results in Suboptimal Growth Longitudinal study with 158 children between 4-16 years with GHD or SGA 33.5% Moderate-to-poor adherence Defined as taking <92% of prescribed rhGH medication Decreased adherence significantly associated with Treatment duration (P=0.001) Par

  51. Slide 51: Somavaratan (VRS-317) Increased Time on Target

    Somavaratan (VRS-317) Increased Time on Target XTEN1 Long Tail of Hydrophilic Amino Acids Reduce Kidney Filtration XTEN2 Short Tail of Hydrophilic Amino Acids Reduce Receptor Mediated Clearance rhGH Same Sequence as Approved Products In clinical development for treatment of children and adults with

  52. Slide 52: Somavaratan: Clinical Experience

    Somavaratan: Clinical Experience Phase 1 - Adults1 30- to 60-fold increase in elimination half-life and longer IGF-I responses, compared with daily rhGH (N=50) Dose-proportional increases in magnitude and duration of IGF-I responses for up to 1 month after a single dose No study drug related serious

  53. Slide 53: VISTA Study Design

    VISTA Study Design 1. Moore et al. J Clin Endocrinol Metab. 2016;101(3):1091-1097. 5.0 mg/kg Monthly 3.5 mg/kg Twice-Monthly 6–12 Months 12–30 Months (ongoing) 0–6 Months Somavaratan Dose Interval Phase 2a (Repeat Dose) Long-Term Safety Study 2.5 mg/kg Twice-Monthly 1.15 mg/kg Weekly 5.0 mg/kg Month

  54. Slide 54: Patient Demographics and Baseline Characteristics

    Patient Demographics and Baseline Characteristics Subjects Enrolled in Phase 2a (n=64) Baseline Age, yeaers, mean (SD) 7.8 (2.4) Gender, n (%) Female 27 (42%) Male 37 (58%) Race, n (%) White 53 (83%) Asian 5 (8%) Black or African American 3 (5%) American Indian or Alaska native 1 (2%) Other 2 (3%) H

  55. Slide 55: Methods: Monitoring Treatment Adherence

    Methods: Monitoring Treatment Adherence Dosing events were reported by the caregiver using a smartphone-compatible electronic patient-reported outcome diary (eDiary) Prior to at-home dosing (initiated at beginning of extension study), caregivers were trained on: Preparation of somavaratan Subcutaneo

  56. Slide 56: Results: Reported Treatment Adherence

    Results: Reported Treatment Adherence after 30 Months Somavaratan Exposure Parameter Somavaratan Starting Regimen Somavaratan Phase 3 Regimen 5.0 mg/kg Monthly (n=22) 2.5 mg/kg Twice-Monthly (n=18) 1.15 mg/kg Weekly* (n=20) 3.5 mg/kg Twice-Monthly (n=58) Doses Completed/Expected 131/131 213/213 195/

  57. Slide 57: Results: Pharmacodynamics

    Results: Pharmacodynamics In all patients receiving 3.5 mg/kg twice-monthly, 8 subjects had peak IGF-I SDS excursions >2, of which 2 were >3.0 (range, 2.01-3.67) During Year 2, IGF-I samples drawn every 3 months, alternating between “peak” (3-5 days after injection) and “trough” (end of dosing cycle

  58. Slide 58: Results: Efficacy – Height Velocity and Height-SDS

    Results: Efficacy – Height Velocity and Height-SDS Mean Height Velocity (HV) and Height-SDS in All Evaluable Patients at 2 Years (n=57) Mean HV ±SD, cm/year Increasing the somavaratan dose to 3.5 mg/kg twice-monthly resulted in Year 2 HV comparable to Year 1 and continued improvement in HT-SDS Lower

  59. Slide 59: Results: Efficacy – Bone, Height, and Chronological Age

    Results: Efficacy – Bone, Height, and Chronological Age Mean increase in bone age and height age exceeded years on study, while differences between chronological and bone age decreased over time Years Bone and Height Age Over Time Chronological Age vs. Bone Age Bone Age Height Age Baseline Year 2 Ba

  60. Slide 60: Year 2 Efficacy Comparators

    Year 2 Efficacy Comparators Selection of the somavaratan 3.5 mg/kg twice-monthly dose is supported by similarities in second year HV (7.83 cm/year) to US estimates (7.9 cm/year) from NCGS Study Second Year Height Velocity (cm/year) Somavaratan – 3.5 mg/kg twice-monthly All subjects with 2-year data

  61. Slide 61: Results: Safety

    Results: Safety Treatment-Related Adverse Events (AEs) Occurring in >1 Subject Adverse Event, n (%) Treatment Period Months 0-6 (n=64) Months 6-12 (n=60) Months 12-18 (n=57) Months 18-24 (n=53) Months 24-30 (n=48) All AEs 34 (53) 10 (17) 6 (11) 4 (8) 6 (13) Injection site pain 31 (48) 6 (10) 2 (4) 1

  62. Slide 62: Conclusions

    Conclusions Phase 3 dose selection is supported by VISTA study results for subjects switched to 3.5 mg/kg twice-monthly Mean peak IGF-I SDS at Phase 3 dose was in upper half of normal range Catch-up growth supported by mean increase in bone age and height age exceeding years on study Improvement in

  63. Slide 63: Investor Day | September 15, 2016

    Investor Day | September 15, 2016

  64. Slide 64: PGHD R&D Program

    PGHD R&D Program Colin Hislop, MD | Chief Medical Officer

  65. Slide 65: Status of Pediatric GHD Clinical Development Program

    Status of Pediatric GHD Clinical Development Program Phase 1b: PK/PD Model to Select Dose/Regimen Phase 2a: Primary Endpoint 6 Month Mean Height Velocity Phase 1b/2a COMPLETED 95% of Phase 2a Patients Rolled Over into Long-Term Safety Study Open to All Children Completing Phase 2a or Phase 3 GHD Chi

  66. Slide 66: Pediatric Phase 3 VELOCITY Trial Enrollment Complete

    Pediatric Phase 3 VELOCITY Trial Enrollment Complete Naïve to treatment, Pre-pubertal GHD Somavaratan 3.5 mg/kg Twice-Monthly 34 µg/kg/day 3:1 Randomization Daily rhGH (Similar Inclusion / Exclusion to Phase 2a) Open Label, Randomized Non-Inferiority Design Somavaratan Dose Selection Validated by Lo

  67. Slide 67: The VISTA Study

    The VISTA Study Previously known as the 13VR3 Extension Study United States, Canada and Europe GHD children completing a somavaratan study 95% of Phase 2a patients rolled over into long-term safety study Currently 48 Subjects continue in study GHD children completing Phase 3 on daily rhGH offered op

  68. Slide 68: Japan Pediatric GHD Phase 2/3 Study J14VR5

    Japan Pediatric GHD Phase 2/3 Study J14VR5 Phase 2 portion enrollment complete n=24 subjects Single dose administration PK/PD assessment over 30 days Comparison between Japanese and Western subjects Subjects transitioning to extension study at 3.5 mg/kg twice-monthly Phase 3 initiation planned Q4 20

  69. Slide 69: 16VR9: PGHD Switch Study

    16VR9: PGHD Switch Study Study to gain real-world experience: Switch from daily Broad PGHD population Auto-injector/Commercial Presentation Provide physicians additional clinical data on how best to use somavaratan for children currently on therapy N=~60 FPI: 1H 2017 A Versartis Study of Somavaratan

  70. Slide 70: PGHD Development Summary

    PGHD Development Summary Versartis clinical development program has been strategic and intentional: Long term safety data - 4 years at time of BLA submission, 5 years at time of launch Clinical studies in geographies representative of current PGHD market Hands on somavaratan experience for PGHD trea

  71. Slide 71: Q & A Session

    Q & A Session

  72. Slide 72: Investor Day | September 15, 2016

    on VERSARTIS Investor Day | September 15, 2016

  73. Slide 73: Introduction: AGHD Speaker

    Introduction: AGHD Speaker Colin Hislop, MD | Chief Medical Officer

  74. Slide 74: Beverly MK Biller, MD

    Beverly MK Biller, MD Dr. Beverly Biller is an endocrinologist and faculty member in the Neuroendocrine Clinical Center at Massachusetts General Hospital. She is also a Professor of Medicine at Harvard Medical School. Dr. Biller received her M.D from the University of Oklahoma College of Medicine. S

  75. Slide 75: Adult growth hormone deficiency and long-acting growth hormone for adults

    Beverly MK Biller, MD Professor of Medicine Harvard Medical School Neuroendocrine Unit Massachusetts General Hospital Adult growth hormone deficiency (AGHD) and long-acting growth hormone (LAGH) for adults

  76. Slide 76: AGHD and LAGH for adults: key questions

    Adult growth hormone deficiency (AGHD) and long-acting growth hormone (LAGH) for adults What is adult GHD? Will LAGH fill an unmet need in the treatment of AGHD?

  77. Slide 77: Case: man with pituitary tumor

    Case 43 year old man - surgery, radiation for benign pituitary tumor Panhypopituitary on triple hormone replacement (thyroid, cortisol, testosterone); otherwise healthy Read about GHD in a well-known publication: “sounds just like me, especially the excess abdominal fat” Worried about his risk of ca

  78. Slide 78: In search of youth

    In search of youth > Anti-aging revolution turns to growth pinay By Nason cuTaks DMI coe bia Story The prince of time: Nolte, 59, takes HGH. Boomers believe they’ve found a fountain of youth in a syringe To fight the onslaught of age, many are spending big bucks to inject human growth hormone every

  79. Slide 79: Illicit use by athletes

    Illicit use by athletes Bodybuilding Baseball Olympics

  80. Slide 80: GH studied in adults with various conditions

    GH studied in adults with: Aging (“somatopause”) Cardiomyopathy Catabolic states Respiratory failure Burns AIDS wasting * Short bowel syndrome * GH deficiency * Childhood onset (CO) Adult onset (AO) *FDA approved uses

  81. Slide 81: Causes of Adult GHD

    Causes of Adult GHD Tumors Pituitary tumors Craniopharyngioma Meningioma Rathke’s cleft cyst Germinoma Others Infiltrative/infectious/inflammatory Hypophysitis Sarcoidosis Histiocytosis X Tb and fungal diseases Others Adapted from Cook DM Growth Horm IGF Res 1999 Surgery Transsphenoidal Craniotomy C

  82. Slide 82: Chronic trauma also a risk

    Aimaretti Clin Endo 2004 Tanriverdi Ann Int Med 2008 Chronic trauma also a risk Retired boxers Pituitary hormone deficiencies in patients with traumatic brain injury (TBI) and subarachnoid hemorrhage (SAH) 3 months after the event

  83. Slide 83: Location of pituitary gland

    From Harris Location of pituitary gland

  84. Slide 84: Head MRI scans

    Normal pituitary gland Large pituitary tumor Head MRI scans

  85. Slide 85: Pituitary hormones and target organs

    Pituitary hormones and target organs From Harris

  86. Slide 86: Somatotroph Axis

    Brain Hypothalamus GHRH + G H Liver Somatotroph Axis Pituitary gland - SMS IGF-I bone fat muscle

  87. Slide 87: Adult GHD - Clinical Features

    Adult GHD - Clinical Features Body composition altered Fat mass increased Lean body mass decreased Skeletal muscle strength decreased Cardiovascular (CV) issues Increased risk of CV death Lipids abnormal Other CV markers abnormal Bone mineral density decreased Quality of life diminished He was most

  88. Slide 88: Cardiovascular deaths in hypopituitary vs healthy people

    0 10 20 30 40 60 50 40 30 20 10 0 Number of Deaths Years After Diagnosis Rosen Lancet Cardiovascular deaths in hypopituitary vs healthy people observed rate in hypopituitary patients not taking GH replacement expected rate in matched population

  89. Slide 89: Possible Mechanisms of Increased CV mortality in adult GHD

    Abnl body composition (high waist/fat, visceral fat) Lipid abnormalities Decreased QOL: low motivation, less exercise Decreased fibrinolytic activity Increased number of arterial plaques Increased intima-media thickness Endothelial cell dysfunction Altered inflammatory process Possible Mechanisms In

  90. Slide 90: Body composition by CT before and on GH

    Bengtson JCEM Before GH 6 months on GH Decreased fat: - subcutaneous - visceral Subcutaneous fat Visceral fat BODY COMPOSITION by CT

  91. Slide 91: Studies all show decreased body fat on GH replacement

    Studies all show decreased body fat on GH replacement -7 -6 -5 -4 -3 -2 -1 0 1 Salomon n=24 Whitehead N=14 Bengtsson N=10 Hansen N=29 Weaver N=22 Baum N=32 Johannsson N=68 Attanasio N=173 Fat (%) Newman Endocrinologist Visceral fat shows the greatest improvement

  92. Slide 92: With GH replacement fat mass decreases, lean mass increases

    With GH replacement fat mass decreases, lean mass increases Body fat Percent Months GH period Placebo period Lean mass Kg Months GH period Placebo period Body composition benefit requires continued GH replacement Biller JCEM

  93. Slide 93: Possible Mechanisms of Increased CV mortality in adult GHD

    Abnl body composition (high waist/fat, visceral fat) Lipid abnormalities Decreased QOL: low motivation, less exercise Decreased fibrinolytic activity Increased number of arterial plaques Increased intima-media thickness Endothelial cell dysfunction Altered inflammatory process Possible Mechanisms In

  94. Slide 94: Carotid artery intima media thickness decreased during GH replacement

    Carotid artery intima media thickness: Decreased during GH replacement Controls Pre-GH Tx GH replacement N = 11 *p<0.001 vs. controls **p<0.01 vs. controls Pfeifer JCEM 6 mo 0.70 3 mo Intima media thickness (mm) 12 mo 18 mo * ** 0.65 0.60 0.55 0.50 0.45 Controls Pretreatment GHD

  95. Slide 95: Summary of cardiovascular risk markers

    Summary of cardiovascular (CV) risk markers GH replacement in GHD reduces markers of CV risk Visceral fat Carotid intima-media thickness Serum Markers of CV risk CRP Interleukin-6 Serum Amyloid A (borderline) Homocysteine Tissue plasminogen activator Lipids (not all studies) Adult GH replacement

  96. Slide 96: Adult GHD - Clinical Features

    Adult GHD - Clinical Features Body composition altered Fat mass increased Lean body mass decreased Skeletal muscle strength decreased Cardiovascular (CV) issues Increased risk of CV death Lipids abnormal Other CV markers abnormal Bone mineral density decreased

  97. Slide 97: GH effects on bone in adults

    GH effects on bone in adults Bone cells have receptors for GH and IGF-I GH and IGF-I stimulate cell division in bone growth plates in vitro GHD is associated with low bone density GH IGF-I IGF-I GH IGF-I

  98. Slide 98: Fracture Frequency in GHD

    Fracture Frequency in GHD 0 5 10 15 20 25 30 GH Deficiency Normals Fracture Frequency (%) * Rosen Eur J Endocrinol Odds ratio for a fracture = 3.49 (1.85-6.56, 95% confidence interval; *P<0.001)

  99. Slide 99: Lumbar spine BMD % change from baseline

    Lumbar spine BMD % change from baseline Duration of treatment (months) GH PL 6 12 18 24 0 ‡ ‡ ‡ * * Men -2 -1 0 1 2 3 4 5 Snyder JBMR ‡ p < 0.05, within group change from baseline * p<0.05 for comparison of change from baseline, GH vs PL 7 US centers: Penn, MGH, Brown, Case Western, Mayo, Oregon, St

  100. Slide 100: Adult GH replacement: bone results summary

    Adult GH replacement Increased bone turnover (formation and resorption) BMD very consistently increased in longer studies ~5% in lumbar spine at 2 years, 10% at 5 years ~2.5% in femoral neck Summary of bone and bone marker results

  101. Slide 101: Adult GHD - Clinical Features

    Adult GHD - Clinical Features Body composition altered Fat mass increased Lean body mass decreased Skeletal muscle strength decreased Cardiovascular (CV) issues Increased risk of CV death Lipids abnormal Other CV markers abnormal Bone mineral density decreased Quality of life diminished

  102. Slide 102: Changes in days of sick leave during GH Replacement

    Changes in days of sick leave during GH Replacement Time, months Sick leave, days / 6 months 0 15 20 10 5 0 Mean ± SEM *P<0.05 vs baseline **P<0.01 ***P<0.001 ** *** ** * Verhelst Clin Endocrinol 6 12 18 24 Before GH

  103. Slide 103: QOL assessment by partners of adults on GH replacement

    QOL assessment by partners of adults on GH replacement Percent reporting (%) Placebo GH P less than: More alert 0.0 69.0 0.0001 More active 3.7 51.8 0.001 Higher endurance 3.6 60.7 0.0001 Less easily annoyed 7.1 28.6 NS Less worried 6.9 37.9 0.05 More extroverted 3.4 37.9 0.01 More industrious 3.3 4

  104. Slide 104: Case - outcome

    43 yo M panhypopituitary due to NF adenoma, TSS, RT Asked for GH after reading USA Today Tested – GH deficiency confirmed Started on daily GH replacement Improvement in: Body composition Bone density Cardiovascular markers Energy Case - outcome

  105. Slide 105: Adult GH replacement benefits

    Adult GH replacement benefits Body composition improved Lipids, cardiovascular markers improved Bone mineral density increased Quality of life improved Well tolerated (side effects mostly dose-related) Yet, many patients are not treated – why?

  106. Slide 106: Barriers to Treatment: GH Replacement Therapy in Adults

    Lack of awareness about efficacy Dosing and monitoring not standardized Diagnosis perceived as difficult Unusual prescribing system Insurance issues/cost Concern about neoplasia Barriers to Treatment GH Replacement Therapy in Adults DAILY INJECTIONS

  107. Slide 107: Case: man with large pituitary tumor

    Case 55 year old man with large pituitary tumor Panhypopituitary on cortisol, thyroid, testosterone Enrolled in a study of weekly long-acting GH Reduction in body fat, increase in lean mass, BMD, QOL When study ended, started commercial daily GH Lost job à no insurance à stopped daily GH New job à i

  108. Slide 108: Compliance with daily GH injections is poor

    Compliance with daily GH injections is poor Rosenfeld & Bakker Endocrine Practice 2008: 14;143-54 Questionnaire on daily GH given to: 326 adolescents/teens 398 parents of children 158 adult patients (shown here) Even in the “Highly Compliant” segment, adult patients missed up to 31 doses over 3 mont

  109. Slide 109: Case: woman with craniopharyngioma

    Case 70 year old woman from a New England state Surgery and radiation for craniopharyngioma Partial hypopituitarism (central hypothyroidism and GHD) Enrolled in a study of GH vs PL 2004-5, did well on GH After study, declined daily commercial GH due to shots Enrolled in weekly LAGH study 2006-7, did

  110. Slide 110: What is AGHD?

    Hormone deficiency associated with pituitary and neurologic disorders in adults Common in patients with other pituitary deficiencies Affect many tissues throughout the body GH replacement improves: body composition muscle strength, endurance bone mineral density cardiovascular markers quality of lif

  111. Slide 111: Will LAGH fill an unmet need in the treatment of AGHD?

    My patients would answer YES! Will LAGH fill an unmet need in the treatment of AGHD?

  112. Slide 112: Investor Day | September 15, 2016

    VERSARTIS =e, Investor Day | September 15, 2016 VERSARTIS

  113. Slide 113: Topline AGHD Phase 2 Data: VITAL (15VR7) Study

    Topline AGHD Phase 2 Data: Results of Ongoing VITAL (15VR7) Study Colin Hislop, MD | Chief Medical Officer

  114. Slide 114: Adult GHD Phase 2: Study Objectives & Design

    Adult GHD Phase 2: Study Objectives & Design Versartis International Trial in Adults with Long Acting Growth Hormone Objectives Evaluation of the safety of individualized dosing of somavaratan Evaluation of the starting doses for each cohort Evaluation of the dose titration plan for each cohort Phas

  115. Slide 115: Adult GHD Phase 2: Demographics

    Adult GHD Phase 2: Demographics Three cohorts with different starting doses based on sensitivity to rhGH Cohort A: Subjects ≥ 35 years of age, Mean Starting Dose = 51.28mg (31.5, 60) Cohort B: Subjects < 35 years of age, Mean Starting Dose = 62.69mg (45.2, 80) Cohort C: Women receiving oral estrogen

  116. Slide 116: Adult GHD Phase 2: Safety

    Adult GHD Phase 2: Safety Adverse Event, n (%) Cohort A (n = 22) Cohort B (n = 6) Cohort C (n = 8) Overall (n = 36) All AEs 7 ( 31.8%) 5 ( 83.3%) 3 ( 37.5%) 15 ( 41.7%) Injection Site Pain 2 ( 9.1%) 1 ( 16.7%) 1 ( 12.5%) 4 ( 11.1%) Headache 3 ( 13.6%) 1 ( 16.7%) 0 ( 0.0%) 4 ( 11.1%) Injection Site E

  117. Slide 117: Pharmacodynamic Response

    Pre-dose Day 7 post-dose Day 21 post-dose Day 28 post-dose Pharmacodynamic Response Mean IGF-I (SD) Throughout Dosing Interval & Study Duration (n=36) Robust IGF-I Response Data Suggest Lower Starting Dose and Shorter Dosing Interval -1.0 2.07 -0.52 -0.93 IGF-I SDS

  118. Slide 118: Pre-Dose IGF-I Impacts Dose Titration

    Pre-Dose IGF-I Impacts Dose Titration Original Titration plan based on Pre-Dose and Day 7 Titration plan does not accurately reflect exposure Therefore, changed titration plan to focus on response at Day 7 New Titration Plan Based on Response at Day 7 IGF-I Throughout Dosing Interval: Cohort A Male

  119. Slide 119: Starting Dose & Titration Plan

    Starting Dose & Titration Plan Somavaratan IGF-I response was robust IGF-I values returned to pre-dose levels by 21 days post dose Titration plan was not ideal to address the high IGF-I at Day 7 No IGF-I associated clinically relevant adverse events 20 mg is the starting dose selected to maintain IG

  120. Slide 120: PK/PD Model Confirms Starting Dose and Administration Frequency

    PK/PD Model Confirms Starting Dose and Administration Frequency Lower Starting Dose, Administered Twice-Monthly: Adequate Exposure Without Accumulation Twice-Monthly Monthly PK/PD Model PK/PD Model: New Starting Dose ~20mg 2 SDS 2 SDS Twice-Monthly Monthly SDS 250 IGF I ng/mL 200 150 100 50 300 2 0

  121. Slide 121: Phase 2 Study: Established Foundation for Phase 3

    Phase 2 Study: Established Foundation for Phase 3 Somavaratan was safe and well tolerated Starting dose, frequency, titration plan & population to be evaluated in ongoing extension study Data available before initiation of Phase 3 Opportunity to confirm elements of Phase 3 design prior to start of t

  122. Slide 122: Investor Day | September 15, 2016

    VERSARTIS =e, Investor Day | September 15, 2016 VERSARTIS

  123. Slide 123: Q & A Session

    =, Q &A Session

  124. Slide 124: Closing Remarks

    Closing Remarks Jay Shepard | Chief Executive Officer

  125. Slide 125: Significant Potential Catalysts to Drive Future Value

    Significant Potential Catalysts to Drive Future Value PEDIATRIC GHD 2017: Initiate Phase 3 Trial 2017: Complete Phase 3 VELOCITY trial Q4 2016: Phase 3 initiation on track Q4 2016 Q3 2017: Topline VELOCITY Results Expected 2018: Expected BLA & MAA Ongoing: 4 years data at time of BLA submission, 5 y

  126. Slide 126: Thank You!

    Thank You!

  127. Slide 127: Versartis Investor Day | September 15, 2016

    VERSARTIS =e, Investor Day | September 15, 2016 VERSARTIS

Versartis — Investor Day (September 2016) on 6ix